Scarica l'app Stockscreener
2.62
6.50%
0.16
Dopo l'orario di chiusura:
2.65
0.03
+1.15%
Kiora Pharmaceuticals Inc Borsa (KPRX) Ultime notizie
Kiora Pharmaceuticals (NASDAQ: KPRX) director receives stock options for 25,000 shares - Stock Titan
Kiora Pharmaceuticals (KPRX) director receives 25,000 stock options grant - Stock Titan
Director at Kiora (KPRX) receives 25,000 stock options at $2.63 strike - Stock Titan
Kiora Pharmaceuticals (KPRX) director granted 25,000 stock options at $2.63 strike - Stock Titan
Kiora Pharmaceuticals (KPRX) director awarded 25,000 stock options - Stock Titan
Kiora (KPRX) director Praveen Tyle receives stock options for 40,000 shares - Stock Titan
Kiora Pharmaceuticals Shareholders Approve Expanded Equity Incentive Plan - TipRanks
Kiora Pharmaceuticals (NASDAQ: KPRX) OKs 1.5M-share equity plan boost and re-elects directors - Stock Titan
Kiora Pharmaceuticals (KPRX) Slips 4.9% as Stock Tests Key Support LevelsAD Line Divergence - newsline.com
Why Did KPRX Stock Surge 17% Pre-Market Today? - Stocktwits
KPRXKiora Pharmaceuticals Inc. stock news, filings & ratings - Quantisnow
Kiora Pharmaceuticals (KPRX) registers 11.8M shares including warrants - Stock Titan
Kiora Pharmaceuticals (KPRX) Holds Steady Near Support as Biotech Sector Faces HeadwindsTrading Ideas - The Legal Advocate
[EFFECT] KIORA PHARMACEUTICALS INC SEC Filing - Stock Titan
Kiora Pharmaceuticals (KPRX) Rallies 5.5%: Key Levels to Watch After Recent UptickStock Buy Zone - newsline.com
Kiora Pharmaceuticals (KPRX) Slips 4.5% as Stock Tests Key Support LevelDealer Gamma - The Legal Advocate
Kiora Pharmaceuticals Q1 2026 Earnings: EPS Beat Masks Continued Pre-Revenue Status as Stock SlipsAnalyst Drop Coverage - Newser
Kiora Pharmaceuticals (NASDAQ: KPRX) registers 11.8M resale shares - Stock Titan
Nantahala reports 9.99% stake in Kiora Pharmaceuticals (KPRX) - Stock Titan
Alyeska files 13G for Kiora (NASDAQ: KPRX) reporting 9.99% stake - Stock Titan
Nantahala holds 148,736 shares in Kiora Pharmaceuticals (KPRX) as 3.388% stake - Stock Titan
TradingKey - TradingKey
Number of shareholders of Kiora Pharmaceuticals, Inc. – NASDAQ:KPRX - TradingView
EDGAR Filing Documents for 0001372514-23-000110 - SEC.gov
KPRX SEC FilingsKIORA PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Kiora (NASDAQ: KPRX) details Q1 2026 results and cash runway to 2028 - Stock Titan
Kiora Pharmaceuticals (NASDAQ: KPRX) reports Q1 loss but sees cash runway into late 2028 - Stock Titan
Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update - TMX Newsfile
Is Kiora Pharmaceuticals (KPRX) stock hiding in plain sight? (Risk Aversion) 2026-05-07Take Profit Levels - newser.com
Kiora Pharmaceuticals Inc expected to post a loss of 71 cents a shareEarnings Preview - TradingView
[ARS] KIORA PHARMACEUTICALS INC SEC Filing - Stock Titan
KPRX Kiora Pharmaceuticals reports far wider Q4 2025 loss than estimates, shares hold flat in today’s trading. - newser.com
Kiora Pharmaceuticals (NASDAQ: KPRX) details 2026 director, pay and equity plan votes - Stock Titan
KPHMW SEC FilingsKiora Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Kiora Pharmaceuticals (KPRX) Industry Outlook | Q4 2025: Earnings UnderperformRevision Downgrade - Cổng thông tin điện tử tỉnh Lào Cai
KPRX Kiora Pharmaceuticals posts far wider Q4 2025 loss than estimates, shares dip nearly 2 percent today.Cycle Outlook - Cổng thông tin điện tử tỉnh Tây Ninh
Eric J. Daniels to Resign as Kiora Chief Development Officer Effective April 17, 2026 - TradingView
Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway - TMX Newsfile
Perceptive Fund (RLAY) reports 9.99% ownership — 438,471 shares - Stock Titan
Breakouts Watch: Is Kiora Pharmaceuticals Inc still a buy after recent gains2026 Action & Advanced Technical Signal Analysis - baoquankhu1.vn
Trend Recap: Will Kiora Pharmaceuticals Inc outperform its industry peers2026 Sentiment & Daily Profit Maximizing Tips - baoquankhu1.vn
What accelerates growth of Kiora Pharmaceuticals (KPRX) Stock | Price at $2.39, Down 3.24%AAII Bearish - newsline.com
Profit Review: Is Kiora Pharmaceuticals Inc a cyclical or defensive stock2026 Breakouts & Breakdowns & Safe Capital Growth Plans - baoquankhu1.vn
KPRX Technical Analysis & ETF Price Forecast - Intellectia AI
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
KPRX Faces Tumultuous Trading: Strategic Moves Amid Market Fluctuations - timothysykes.com
Kiora Pharmaceuticals Surges 23.5% Intraday – What's Fueling the Rally? - Bitget
KiORa Pharmaceuticals (KPRX) Stock: Jumps 24% After $24M Private Placement Deal - parameter.io
Kiora Pharmaceuticals closes $24M private placement By Investing.com - Investing.com South Africa
Kiora Pharmaceuticals’ Stock Analysis amidst Financial Challenges - StocksToTrade
Kiora Pharmaceuticals Inc. Poised for Strategic Expansion Amid Market Challenges - timothysykes.com
According to the latest filings disclosed by the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Kiora Pharmaceuticals (stock code: KPRX) plans to privately place 438,471 shares of its common stock to specific investors. - Bitget
Kiora Pharmaceuticals Announces $5 Million Private Placement Financing - TipRanks
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):